Afirma基因测序分类器与基因表达分类器在细胞学不确定甲状腺结节中的独立比较
该回顾性研究比较了Afirma基因表达分类器(GEC)与基因测序分类器(GSC)在Bethesda III或IV细胞学甲状腺结节中的良性呼叫率(BCR)。共评估600个结节(GEC 486个,GSC 114个),GSC的BCR为65.8%,显著高于GEC的47.9%(p=0.0006),差异主要见于Hürthle细胞细胞学结节。
要点
- GSC在不确定甲状腺结节中的良性呼叫率显著高于GEC(65.8% vs 47.9%,p=0.0006)。
- GSC的BCR优势主要体现在Hürthle细胞细胞学结节中。
- GSC可能进一步减少不必要的手术管理。
核心结论
- GSC相比GEC在不确定甲状腺结节中具有更高的良性呼叫率,尤其在Hürthle细胞细胞学结节中,可能进一步减少手术管理。
研究设计与样本
- 回顾性分析2011年1月1日至2018年8月27日期间在本机构接受GEC或GSC检测的Bethesda III或IV细胞学甲状腺结节(≥1 cm),共600个结节(563例患者),GEC组486个,GSC组114个。
主要发现
- GEC组良性呼叫率为47.9%(233/486),GSC组为65.8%(75/114),差异显著(p=0.0006)。
- GEC组Hürthle细胞细胞学结节占20.4%(99/486),GSC组占27.2%(31/114),两组间无显著差异(p=0.28)。
- 在Bethesda III结节中,GSC对Hürthle细胞结节的良性呼叫率显著高于GEC(p=0.006),而架构或细胞异型性结节的BCR相似。
- 在Bethesda IV滤泡性肿瘤可疑结节中,GEC与GSC的BCR相似(p=0.68);但在Hürthle细胞肿瘤可疑结节中,GSC的BCR为68.2%(15/22),GEC为16.4%(10/61),差异显著(p<0.0001)。
- 切除结节中可疑结果的阳性预测值:GSC为50%(16/32),GEC为33.9%(75/221),差异无统计学意义(p=0.1)。
临床怎么用
- 对于细胞学不确定的甲状腺结节,尤其是Hürthle细胞细胞学结节,GSC可提供更高的良性呼叫率,有助于减少诊断性手术。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: For thyroid nodules with indeterminate cytology, the Afirma Gene Expression Classifier (GEC) identified benign nodules to reduce diagnostic surgery, though many nodules classified as suspicious still proved histopathologically benign. The current Afirma Genomic Sequencing Classifier (GSC) demonstrates improved specificity, suggesting more nodules will have a benign result (benign call rate [BCR]), but independent data are needed to confirm this in clinical practice. Methods: Retrospective analysis was performed of all Bethesda III or IV cytology thyroid nodules ≥1 cm tested with GEC (between January 1, 2011, and July 19, 2017) or GSC (between July 20, 2017, and August 27, 2018) at the authors' institution. Afirma testing was not performed reflectively for all nodules with Bethesda III or IV cytology, but rather was applied based on physician-patient decision making. Demographic, sonographic, and cytologic data were collected. The BCR for GEC- versus GSC-tested nodules was compared and further stratified by Bethesda classifications. Results: The study evaluated 600 nodules in 563 patients tested with either GEC (n = 486) or GSC (n = 114). The BCR was 233/486 (47.9%) for the GEC compared to 75/114 (65.8%) for the GSC (p = 0.0006). Hürthle-cell cytology was present in 99/486 (20.4%) nodules in the GEC group compared to 31/114 (27.2%) nodules in the GSC group (p = 0.28). The GSC BCR was significantly higher than the GEC BCR for Bethesda III nodules characterized by Hürthle cells (p = 0.006), but the BCRs were similar for nodules with architectural or cytologic atypia. In Bethesda IV nodules suspicious for follicular neoplasm, BCR for the GEC and GSC were similar (p = 0.68), but for cytology suspicious for Hürthle-cell neoplasm, the GSC BCR was 68.2% (15/22) compared to the GEC BCR of 16.4% (10/61; p < 0.0001). Positive predictive value in resected nodules with a suspicious result was 16/32 (50%) for GSC nodules and 75/221 (33.9%) for GEC nodules (p = 0.1). Conclusions: The higher BCR for the GSC compared to the GEC for indeterminate thyroid nodules, predominantly among nodules with Hürthle-cell cytology, will likely lead to further reduction in surgical management.
引用
- Angell TE, Heller HT, Cibas ES, et al. Independent Comparison of the Afirma Genomic Sequencing Classifier and Gene Expression Classifier for Cytologically Indeterminate Thyroid Nodules. Thyroid. 2019. PMID: 30803388. doi:10.1089/thy.2018.0726
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。